Insider Selling: Ultragenyx Pharmaceutical (NASDAQ:RARE) Director Sells 2,000 Shares of Stock

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Director Corazon (Corsee) Sanders sold 2,000 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $25.05, for a total value of $50,100.00. Following the completion of the transaction, the director owned 21,095 shares of the company’s stock, valued at approximately $528,429.75. This trade represents a 8.66% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Ultragenyx Pharmaceutical Trading Up 4.2%

Ultragenyx Pharmaceutical stock traded up $1.03 on Monday, hitting $25.38. 1,479,218 shares of the stock traded hands, compared to its average volume of 2,092,176. Ultragenyx Pharmaceutical Inc. has a 1 year low of $18.29 and a 1 year high of $42.37. The firm has a market cap of $2.50 billion, a P/E ratio of -4.15 and a beta of 0.37. The business’s fifty day simple moving average is $23.99 and its 200 day simple moving average is $25.08.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings results on Tuesday, May 5th. The biopharmaceutical company reported ($1.84) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.49) by ($0.35). Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 91.03%.The business had revenue of $136.00 million during the quarter, compared to analysts’ expectations of $158.19 million. During the same period in the prior year, the company earned ($1.57) earnings per share. The firm’s quarterly revenue was down 2.2% compared to the same quarter last year. As a group, analysts predict that Ultragenyx Pharmaceutical Inc. will post -4.53 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on RARE shares. Canaccord Genuity Group decreased their target price on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a research note on Wednesday, February 18th. The Goldman Sachs Group downgraded Ultragenyx Pharmaceutical from a “buy” rating to a “neutral” rating and cut their price target for the stock from $61.00 to $25.00 in a research note on Tuesday, March 24th. Weiss Ratings raised Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, May 8th. Wells Fargo & Company lifted their price objective on Ultragenyx Pharmaceutical from $45.00 to $47.00 and gave the company an “overweight” rating in a research note on Wednesday, May 6th. Finally, JPMorgan Chase & Co. dropped their target price on Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating on the stock in a report on Thursday, March 12th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Ultragenyx Pharmaceutical currently has a consensus rating of “Moderate Buy” and an average price target of $59.56.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Assetmark Inc. grew its holdings in shares of Ultragenyx Pharmaceutical by 1,706.7% during the third quarter. Assetmark Inc. now owns 1,084 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 1,024 shares during the last quarter. Huntington National Bank raised its holdings in Ultragenyx Pharmaceutical by 56.2% in the 3rd quarter. Huntington National Bank now owns 1,092 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 393 shares during the last quarter. Danske Bank A S bought a new position in Ultragenyx Pharmaceutical in the 3rd quarter valued at approximately $39,000. Parallel Advisors LLC boosted its stake in Ultragenyx Pharmaceutical by 778.4% during the 1st quarter. Parallel Advisors LLC now owns 1,625 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 1,440 shares during the last quarter. Finally, Smartleaf Asset Management LLC boosted its stake in Ultragenyx Pharmaceutical by 205.4% during the 3rd quarter. Smartleaf Asset Management LLC now owns 1,738 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 1,169 shares during the last quarter. 97.67% of the stock is owned by hedge funds and other institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.